Functional imaging in Huntington's disease

Experimental Neurology

Volumn 216, Issue 2, 2009, Pages 272-277

  Paulsen, Jane S ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

fMRI; Functional imaging; Huntington's disease; PET

Indexed keywords

DOPAMINE RECEPTOR; ETHYLSPIPERONE F 18; FLUORODEOXYGLUCOSE F 18; METHYLSPIPERONE CN 11; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

DIAGNOSTIC IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; HUNTINGTON CHOREA; MEDICAL RESEARCH; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; TISSUE REPAIR;

BRAIN; BRAIN MAPPING; HUMANS; HUNTINGTON DISEASE; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 62149136286     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2008.12.015     Document Type: Review

References (89)

1. Albin R.L., Young A.B., Penney J.B., Handelin B., Balfour R., Anderson K.D., Markel D.S., Tourtellotte W.W., and Reiner A. Abnormalities of striatal projection neurons and N-methyl-d-aspartate receptors in presymptomatic Huntington's disease. N. Engl. J. Med. 332 (1990) 1293-1298
2. Alexander G.E., DeLong M.R., and Strick P.I. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 9 (1986) 357-381
3. Andrews T.C., Weeks R.A., Turjanski N., Gunn R.N., Watkins L.H., Sahakian B., Hodges J.R., Rosser A.E., Wood N.W., and Brooks D.J. Huntington's disease progression. PET and clinical observations. Brain 122 (1999) 2353-2363
4. Antonini A., Leenders K.L., Spiegel R., Meier D., Vontobel P., Weigell-Weber M., Sanchez-Pernaute R., de Yebenez J.G., Boesiger P., Weindl A., and Maguire R.P. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 119 (1996) 2085-2095
5. Aylward E.H., Codori A., Barta P., Pearlson G., Harris G., and Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington's disease. Arch. Neurol. 53 (1996) 1293-1296
6. Aylward E.H., Li Q., Stine O.C., Ranen N., Sherr M., Barta P.E., Bylsma F.W., Pearlson G.D., and Ross C.A. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 48 (1997) 394-399
7. Aylward E.H., Sparks B.F., Field K.M., Yallapragada V., Shpritz B.D., Rosenblatt A., Brandt J., Gourley L.M., Liang K., Zhou H., Margolis R.L., and Ross C.A. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 63 (2004) 66-72
8. Bachoud-Levi A.C., Gaura V., Brugieres P., Lefaucheur J.P., Boisse M.F., Maison P., Baudic S., Ribeiro M.J., Bourdet C., Remy P., Cesaro P., Hantraye P., and Peschanski M. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol. 5 (2006) 303-309
9. Backman L., Robins-Wahlin T.B., Lundin A., Ginovart N., and Farde L. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 120 Pt 12 (1997) 2207-2217
10. Bartenstein P., Weindl A., Spiegel S., Boecker H., Wenzel R., Ceballos-Baumann A.O., Minoshima S., and Conrad B. Central motor processing in Huntington's disease. A PET study. Brain 120 Pt 9 (1997) 1553-1567
11. Beglinger L.J., Nopoulos P.C., Jorge R.E., Langbehn D.R., Mikos A.E., Moser D.J., Duff K., Robinson R.G., and Paulsen J.S. White matter volume and cognitive dysfunction in early Huntington's disease. Cogn. Behav. Neurol. 18 (2005) 102-107
12. Bhide P.G., Day M., Sapp E., Schwarz C., Sheth A., Kim J., Young A.B., Penney J., Golden J., Aronin N., and DiFiglia M. Expression of normal and mutant huntingtin in the developing brain. J. Neurosci. 16 (1996) 5523-5535
13. Brown G.G., and Eyler L.T. Methodological and conceptual issues in functional magnetic resonance imaging: applications to schizophrenia research. Annu. Rev. Clin. Psychol. 2 (2006) 51-81
14. Cabeza R., and Nyberg L. Imaging cognition II: an empirical review of 275 PET and fMRI studies. J. Cogn. Neurosci. 12 (2000) 1-47
15. Ciarmiello A., Cannella M., Lastoria S., Simonelli M., Frati L., Rubinsztein D.C., and Squitieri F. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J. Nucl. Med. 47 (2006) 215-222
16. Clark V.P., Lai S., and Deckel A.W. Altered functional MRI responses in Huntington's disease. NeuroReport 13 (2002) 703-706
17. Clower D.M., Dum R.P., and Strick P.L. Basal ganglia and cerebellar inputs to 'AIP'. Cereb. Cortex 15 (2005) 913-920
18. Dierks T., Linden D.E., Hertel A., Gunther T., Lanfermann H., Niesen A., Frolich L., Zanella F.E., Hor G., Goebel R., and Maurer K. Multimodal imaging of residual function and compensatory resource allocation in cortical atrophy: a case study of parietal lobe function in a patient with Huntington's disease. Psychiatry Res. 90 (1999) 67-75
19. Duff K., Paulsen J.S., Beglinger L.J., Langbehn D.R., and Stout J.C. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol. Psychiatry 62 (2007) 1341-1346
20. Duyao M., Ambrose C., Myers R., Novelletto A., Persichetti F., Frontali M., Folstein S., Ross C., Franz M., Abbott M., et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet. 4 (1993) 387-392
21. Feigin A., Fukuda M., Dahawan V., Przedborski S., Jackson-Lewis V., Mentis J.J., Moeller J.R., and Eidelberg D. Metabolic correlates of levodopa response in Parkinson's disease. Neurology 57 (2001) 2083-2088
22. Feigin A., Ghilardi M.F., Huang C., Ma Y., Carbon M., Guttman M., Paulsen J.S., Ghez C.P., and Eidelberg D. Preclinical Huntington's disease: compensatory brain responses during learning. Ann. Neurol. 59 (2006) 53-59
23. Feigin A., Tang C., Ma Y., Mattis P., Zgaljardic D., Guttman M., Paulsen J.S., Dhawan V., and Eidelberg D. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 130 (2007) 2858-2867
24. Friston K.J., Tononi G., Reeke Jr. G.N., Sporns O., and Edelman G.M. Value-dependent selection in the brain: simulation in a synthetic neural model. Neuroscience 59 (1994) 229-243
25. Gaura V., Bachoud-Levi A.C., Ribeiro M.J., Nguyen J.P., Frouin V., Baudic S., Brugieres P., Mangin J.F., Boisse M.F., Palfi S., Cesaro P., Samson Y., Hantraye P., Peschanski M., and Remy P. Striatal neural grafting improves cortical metabolism in Huntington's disease patients. Brain 127 (2004) 65-72
26. Georgiou-Karistianis N., Sritharan A., Farrow M., Cunnington R., Stout J., Bradshaw J., Churchyard A., Brawn T.L., Chua P., Chiu E., Thiruvady D., and Egan G. Increased cortical recruitment in Huntington's disease using a Simon task. Neuropsychologia 45 (2007) 1791-1800
27. Ginovart N., Lundin A., Farde L., Halldin C., Backman L., Swahn C.G., Pauli S., and Sedvall G. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 120 (1997) 503-514
28. Goldberg T.E., Saint-Cyr J.A., and Weinberger D.R. Assessment of procedural learning and problem solving in schizophrenic patients by Tower fo Hanoi type tasks. J. Neuropsychiatry Clin. Neurosci. 2 (1990) 165-173
29. Gomez-Anson B., Alegret M., Munoz E., Sainz A., Monte G.C., and Tolosa E. Decreased frontal choline and neuropsychological performance in preclinical Huntington disease. Neurology 68 (2007) 906-910
30. Gusella J.F., McNeil S., Persichetti F., Srinidhi J., Novelletto A., Bird E., Faber P., Vonsattel J.P., Myers R.H., and MacDonald M.E. Huntington's disease. Cold Spring Harbor Symp. Quant. Biol. 61 (1996) 615-626
31. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., Jones R., Rye D., Ferrante R.J., Hersch S.M., and Li X.J. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19 (1999) 2522-2534
32. Hagglund J., Aquilonius S.M., Eckernas S.A., Hartvig P., Lundquist H., Gullberg P., and Langstrom B. Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone. Acta Neurol. Scand. 75 (1987) 87-94
33. Hanson J.M., Duff K., Hollingworth A., Paradiso S., and Paulsen J.S. Eye-Tracking as a Potential Biomarker in Huntington's Disease, 12th International Congress of Parkinson's Disease and Movement Disorders (2008), Chicago, IL
34. Hauser R.A., Furtado S., Cimino C.R., Delgado H., Eichler S., Schwartz S., Scott D., Nauert G.M., Soety E., Sossi V., Holt D.A., Sanberg P.R., Stoessl A.J., and Freeman T.B. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 58 (2002) 687-695
35. Hayden M.R., Martin W.R., Stoessl A.J., Clark C., Hollenberg S., Adam M.J., Ammann W., Harrop R., Rogers J., and Ruth T. Positron emission tomography in the early diagnosis of Huntington's disease. Neurology 36 (1986) 888-894
36. Hayden M.R., Hewitt J., Stoessel A.J., Clark C., Ammann W., and Martin W.R. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease. Neurology 37 (1987) 1441-1447
37. Hickey M.A., and Chesselet M.F. Apoptosis in Huntington's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 255-265
38. Hickey M.A., and Chesselet M.F. The use of transgenic and knock-in mice to study Huntington's disease. Cytogenet. Genome Res. 100 (2003) 276-286
39. Holthoff V.A., Koeppe R.A., Frey K.A., Penney J.B., Markel D.S., Kuhl D.E., and Young A.B. Positron emission tomography measures of benzodiazepine receptors in Huntington's disease. Ann. Neurol. 34 (1993) 76-81
40. Horwitz B., and Glabus M.F. Neural modeling and functional brain imaging: the interplay between the data-fitting and simulation approaches. Int. Rev. Neurobiol. 66 (2005) 267-290
41. Horwitz B., and Poeppel D. How can EEG/MEG and fMRI/PET data be combined?. Hum. Brain Mapp. 17 (2002) 1-3
42. Hoshi E., Tremblay L., Feger J., Carras P.L., and Strick P.L. The cerebellum communicates with the basal ganglia. Nat. Neurosci. 8 (2005) 1491-1493
43. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
44. Kelly R.M., and Strick P.L. Macro-architecture of basal ganglia loops with the cerebral cortex: use of rabies virus to reveal multisynaptic circuits. Prog. Brain Res. 143 (2004) 449-459
45. Kim J.S., Reading S.A., Brashers-Krug T., Calhoun V.D., Ross C.A., and Pearlson G.D. Functional MRI study of a serial reaction time task in Huntington's disease. Psychiatry Res. 131 (2004) 23-30
46. Kremer B., Clark C.M., Almqvist E.W., Raymond L.A., Graf P., Jacova C., Mezei M., Hardy M.A., Snow B., Martin W., and Hayden M.R. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 53 (1999) 1000-1011
47. Kuhl D.E., Phelps M.E., Markham C.H., Metter E.J., Riege W.H., and Winter J. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann. Neurol. 12 (1982) 425-434
48. Kuhl D.E., Metter E.J., Riege W.H., and Markham C.H. Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease. Ann. Neurol. 15 Suppl (1984) S119-S125
49. Kuhl D.E., Markham C.H., Metter E.J., Riege W.H., Phelps M.E., and Mazziotta J.C. Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease. Res. Publ.- Assoc. Res. Nerv. Ment. Dis. 63 (1985) 199-209
50. Kunig G., Leenders K.L., Sanchez-Pernaute R., Antonini A., Vontobel P., Verhagen A., and Gunther I. Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography. Ann. Neurol. 47 (2000) 644-648
51. Kuwert T., Lange H.W., Langen K.J., Herzog H., Aulich A., and Feinendegen L.E. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain 113 Pt 5 (1990) 1405-1423
52. Laforet G.A., Sapp E., Chase K., McIntyre C., Boyce F.M., Campbell M., Cadigan B.A., Warzecki L., Tagle D.A., Reddy P.H., Cepeda C., Calvert C.R., Jokel E.S., Klapstein G.J., Ariano M.A., Levine M.S., DiFiglia M., and Aronin N. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J. Neurosci. 21 (2001) 9112-9123
53. Lawrence A.D., Hodges J.R., Rosser A.E., Kershaw A., Ffrench-Constant C., Rubinsztein D.C., Robbins T.W., and Sahakian B.J. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 121 (1998) 1329-1341
54. Leenders K.L., Frackowiak R.S., Quinn N., and Marsden C.D. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. Mov. Disord. 1 (1986) 69-77
55. Magnotta V.A., Adix M.L., Caprahan A., Lim K., Gollub R., and Andreasen N.C. Investigating connectivity between the cerebellum and thalamus in schizophrenia using diffusion tensor tractography: a pilot study. Psychiatry Res. 163 (2008) 193-200
56. Mazziotta J.C., Phelps M.E., Pahl J.J., Huang S.C., Baxter L.R., Riege W.H., Hoffman J.M., Kuhl D.E., Lanto A.B., Wapenski J.A., and Markham C.H. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N. Engl. J. Med. 316 (1987) 357-362
57. Murphy A.N., Fiskum G., and Beal M.F. Mitochondria in neurodegeneration: bioenergetic function in cell life and death. J. Cereb. Blood Flow Metab. 19 (1999) 231-245
58. Myers R.H., Sax D.S., Koroshetz W.J., Mastromauro C., Cupples L.A., Kiely D.K., Pettengill F.K., and Bird E.D. Factors associated with slow progression in Huntington's disease. Arch. Neurol. 48 (1991) 800-804
59. Nopoulos P., Magnotta V.A., Mikos A., Paulson H., Andreasen N.C., and Paulsen J.S. Morphology of the cerebral cortex in preclinical Huntington's disease. Am. J. Psychiatry 164 (2007) 1428-1434
60. Pallier P.N., Maywood E.S., Zheng Z., Chesham J.E., Inyushkin A.N., Dyball R., Hastings M.H., and Morton A.J. Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease. J. Neurosci. 27 (2007) 7869-7878
61. Paulsen J., Nehl C., and Guttman M. Basal ganglia and movement disorders. In: Rizzo M., and Eslinger P.J. (Eds). Principles and Practice of Behavioral Neurology and Neuropsychology (2004), W.B. Saunders, Philadelphia, PA 525-550
62. Paulsen J.S., Zimbelman J.L., Hinton S.C., Langbehn D.R., Leveroni C.L., Benjamin M.L., Reynolds N.C., and Rao S.M. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's disease. AJNR Am. J. Neuroradiol. 25 (2004) 1715-1721
63. Paulsen J.S., Hayden M., Stout J.C., Langbehn D.R., Aylward E., Ross C.A., Guttman M., Nance M., Kieburtz K., Oakes D., Shoulson I., Kayson E., Johnson S., and Penziner E. Preparing for preventive clinical trials: the Predict-HD study. Arch. Neurol. 63 (2006) 883-890
64. Paulsen J.S., Langbehn D.R., Stout J.C., Aylward E., Ross C.A., Nance M., Guttman M., Johnson S., MacDonald M., Beglinger L.J., Duff K., Kayson E., Biglan K., Shoulson I., Oakes D., and Hayden M. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatry 79 (2008) 874-880
65. Pavese N., Andrews T.C., Brooks D.J., Ho A.K., Rosser A.E., Barker R.A., Robbins T.W., Sahakian B.J., Dunnett S.B., and Piccini P. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 126 (2003) 1127-1135
66. Perry T.L., Hansen S., and Kloster M. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain. N. Engl. J. Med. 288 (1973) 337-342
67. Reading S.A., Dziorny A.C., Peroutka L.A., Schreiber M., Gourley L.M., Yallapragada V., Rosenblatt A., Margolis R.L., Pekar J.J., Pearlson G.D., Aylward E., Brandt J., Bassett S.S., and Ross C.A. Functional brain changes in presymptomatic Huntington's disease. Ann. Neurol. 55 (2004) 879-883
68. Rosas H.D., Goodman J., Chen Y.I., Jenkins B.G., Kennedy D.N., Makris N., Patti M., Seidman L.J., Beal M.F., and Koroshetz W.J. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology 57 (2001) 1025-1028
69. Rosas H.D., Hevelone N.D., Zaleta A.K., Greve D.N., Salat D.H., and Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 65 (2005) 745-747
70. Rosas H.D., Salat D.H., Lee S.Y., Zaleta A.K., Pappu V., Fischl B., Greve D., Hevelone N., and Hersch S.M. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 131 (2008) 1057-1068
71. Sax D.S., O, Donnell B., Butters N., Menzer L., Montgomery K., and Kayne H.L. Computerized tomographic, neurologic, and neuropsychological correlates of Huntington's disease. Int. J. Neurosci. 18 (1983) 21-36
72. Schacter D.L., and Wagner A.D. Medial temporal lobe activations in fMRI and PET studies of episodic encoding and retrieval. Hippocampus 9 (1999) 7-24
73. Sedvall G., Karlsson P., Lundin A., Anvret M., Suhara T., Halldin C., and Farde L. Dopamine D1 receptor number-a sensitive PET marker for early brain degeneration in Huntington's disease. Eur. Arch. Psychiatry Clin. Neurosci. 243 (1994) 249-255
74. Solomon A.C., Stout J.C., Johnson S.A., Langbehn D.R., Aylward E.H., Brandt J., Ross C.A., Beglinger L., Hayden M.R., Kieburtz K., Kayson E., Julian-Baros E., Duff K., Guttman M., Nance M., Oakes D., Shoulson I., Penziner E., and Paulsen J.S. Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia 45 (2007) 1767-1776
75. Starkstein S., Brandt J., Folstein S.E., Strauses M.E., Berthier M.L., Pearlson G.D., Wong D., McDonnell A., and Folstein M. Neuropsychological and neuroradiological correlates of Huntington's disease. J. Neurol. Neurosurg. Psychiatry 51 (1988) 1259-1263
76. Starkstein S.E., Brandt J., Bylsma F.W., Peyser C.E., Folstein M., and Folstein S.E. Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance study. Neuroradiology 34 (1992) 487-489
77. Tagamets M.A., and Horwitz B. Interpreting PET and fMRI measures of functional neural activity: the effects of synaptic inhibition on cortical activation in human imaging studies. Brain Res. Bull. 54 (2001) 267-273
78. Thiruvady D.R., Georgiou-Karistianis N., Egan G.F., Ray S., Sritharan A., Farrow M., Churchyard A., Chua P., Bradshaw J.L., Brawn T.L., and Cunnington R. Functional connectivity of the prefrontal cortex in Huntington's disease. J. Neurol. Neurosurg. Psychiatry 78 (2007) 127-133
79. Tobin A.J., and Signer E.R. Huntington's disease: the challenge for cell biologists. Trends Cell Biol. 10 (2000) 531-536
80. Turjanski N., Lees A.J., and Brooks D.J. In vivo studies on striatal dopamine D1 and D2 site binding in l-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 49 (1997) 717-723
81. Vonsattel J.P., and DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 57 (1998) 369-384
82. Weeks R.A. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol. 40 (1996) 49-54
83. Whitlock, K.B., Stout, J.C., Queller, S., Langbehn, D.R., Carlozzi, N.E., Paulsen, J.S., and Predict-HD Investigators of the Huntington Study Group, 2007. Item Reduction of the University of Pennsylvania Smell ID Test: Preparation for Clinical Trials in pre-HD using the Predict Cohort, Inaugural Huntington Disease Clinical Research Symposium, Boston, MA.
84. Wolf R.C., Vasic N., Schonfeldt-Lecuona C., Landwehrmeyer G.B., and Ecker D. Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI. Brain 130 (2007) 2845-2857
85. Wolf R.C., Sambataro F., Vasic N., Schonfeldt-Lecuona C., Ecker D., and Landwehrmeyer B. Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington's disease. Exp. Neurol. (2008)
86. Wolf R.C., Vasic N., Schonfeldt-Lecuona C., Ecker D., and Landwehrmeyer G.B. [Functional imaging of cognitive processes in Huntington's disease and its presymptomatic mutation carriers]. Nervenarzt 79 (2008) 408-420
87. Young A.B., Penney J.B., Starosta-Rubenstein S., Markel D.S., Berent S., Giordani B., Ehrenkaufer R., Jewett D., and Hichwa R. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann. Neurol. 20 (1986) 296-303
88. Young A.B., Penney J.B., Starosta-Rubinstein S., Markel D., Berent S., Rothley J., Betley A., and Hichwa R. Normal caudate glucose metabolism in persons at risk for Huntington's disease. Arch. Neurol. 44 (1987) 254-257
89. Zimbelman J.L., Paulsen J.S., Mikos A., Reynolds N.C., Hoffmann R.G., and Rao S.M. fMRI detection of early neural dysfunction in preclinical Huntington's disease. J. Int. Neuropsychol. Soc. 13 (2007) 758-769